International ethical guidelines for biomedical research involving human subjects Council for International Organizations of Medical Sciences (CIOMS), Aug, 2002

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2003, Vol. 8 ›› Issue (1): 107-110.

Previous Articles Next Articles

International ethical guidelines for biomedical research involving human subjects Council for International Organizations of Medical Sciences (CIOMS), Aug, 2002

Translated by BO Qing-Yan, Revised by XIONG Ning-Ning¹, WU Jing¹

Nanjing University of Traditional Chinese Medicine, Nanjing 210029 Jiangsu; ¹National Base for Drug clinical Trial, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing 210029 Jiangsu

Received:2002-11-27 Revised:2002-12-15 Published:2020-11-25

Abstract

Abstract: This is the third version in the series of biomedical-research ethical guidelines issued by CIOMS since 1982.The members of redrafting group come from Africa, Asia, Latin America, Europe and Latin America, the United States and the CIOMS secretariat.Its core consists of 21 guidelines with commentaries.Like those of 1982 and 1993, the 2002 CIOMS guidelines are designed to be of use to countries in defining national policies on the ethics of biomedical research involving human subjects, applying ethical standards in local circumstances, and establishing or improving ethical review mechanisms.

Key words: medical ethics, clinical trial, Council for International Organizations of Medical Sciences, guidelines

CLC Number:

B8205
R969.4

BO Qing-Yan, Revised by XIONG Ning-Ning, WU Jing. International ethical guidelines for biomedical research involving human subjects Council for International Organizations of Medical Sciences (CIOMS), Aug, 2002[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(1): 107-110.

[1]	WANG Anjing, WANG Yaya, LIANG Xuan, YAN Yajie, SU Jing, LI Caidong. Research progress on mechanisms and therapeutic drugs of peroxisome proliferator-activated receptor in treatment of cholestatic liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 796-808.
[2]	WANG Zhi, ZHOU Xin, HE Xueru, FU Yuhao, XUN Xuejiao, LI Ying, DONG Zhanjun. Clinical research progress of palbociclib in treatment of breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 205-213.
[3]	DAI Jiahui, SUN Sijia, XIE Xuefeng. Quality management and indicator system for clinical trials of medical devices [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 51-58.
[4]	CHEN Jianfang, LOU Donghua. Design of case report form for oncology clinical trials based on CDASH [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 762-767.
[5]	LIU Xing, LU Xiaoran, WU Ying, YU Haitao, WANG Xiaomin. Ethical analysis and countermeasures of artificial intelligence application in clinical trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 322-327.
[6]	ZHU Lili, ZHU Xiuxiu, WANG Wenjun, ZHANG Hailin, LIN Li. Clinical trials of inhalation in pediatric population in China [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 178-183.
[7]	LI Shanshan, GU Jingwen, ZHANG Jing, YANG Haijing, LIU Wei, YU Yiqi, ZHANG Wenhong. Design and evaluation of clinical trials of COVID-19 vaccine and monoclonal neutralizing antibody [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 190-197.
[8]	DENG Kunhong, LIU Yaxin, SUN Yuanyuan, CHEN Wenjing, YANG Nan, HU Zhanqing, CHEN Kaifeng, HUANG Jie, XIANG Yuxia, YANG Guoping. Literature analysis of the design and results of the First-In-Human clinical trials of drugs from 2009 to 2020 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 77-85.
[9]	ZHENG Ying, ZHANG Ling, YAO Li, WANG Qianhe, ZHU Kexiang. Research progress of PARP inhibitors in pancreatic cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 108-115.
[10]	SHE Zhihua, CHEN Zhou, LIANG Songyue. Construction of informatization system of drug clinical trials ethical review based on cloud architecture [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1023-1030.
[11]	SONG Yan, GAO Linyan, ZHANG Yanping, LI Xiang, ZHANG Lan. Application of medical failure mode and effect analysis in blood sample management in phase I clinical trials#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1031-1036.
[12]	OUYANG Chenxi, HUANG Jie, XIANG Yuxia, WANG Xiaomin. Ethical issues and countermeasures of early phase trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 802-807.
[13]	HUANG Lihong, WANG Ling, YAN Fangrong, WEI Zhaohui, ZHAO Yang, XIA Jielai, CHEN Feng. New perspectives on the principle of intention to treat in clinical trials#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 449-453.
[14]	Pazilaiti YASEN, YUAN Hao, LU Hong, ZHENG Ya, WANG Yuping, ZHOU Yongning. Research progress in clinical trials of targeted drugs for gastric cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 454-461.
[15]	ZHANG Qian, HU Wei, YU Bin, QIN Huiling, CHEN Mingzhuang, LU Chao. Information construction of drug clinical trials based on literature analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 182-189.

International ethical guidelines for biomedical research involving human subjects Council for International Organizations of Medical Sciences (CIOMS), Aug, 2002

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments